Journal profile · ONCOLOGY
Photodiagnosis and Photodynamic Therapy
ISSN 1572-1000 · eISSN 1873-1597 · Elsevier · Netherlands · Quarterly · Founded 2004
Photodiagnosis and Photodynamic Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.64; fully open access; APC about USD 2,960; median 56 days to acceptance (129 articles, last 24 months); community-reported acceptance: fairly easy; 852 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Photodiagnosis and Photodynamic Therapy is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Photodynamic Therapy Research Studies, Nanoplatforms for cancer theranostics and Laser Applications in Dentistry and Medicine, together about 50.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Official Journal of the European Platform for Photodynamic Medicine Affiliated with the International Photodynamic Association Also affiliated with the British Medical Laser Association and the Polish Society for Photodynamic MedicineINDEXED in MEDLINE/PubMed, SciSearch/Science Citation Index Expanded, Current Contents/Clinical Medicine.Aims and Scope: Photodiagnosis and Photodynamic Therapy is an international journal for the dissemination of scientific knowledge and clinical developments of Photodiagnosis and Photodynamic Therapy in all medical specialties. The journal publishes original articles, review articles, case presentations, "how-to-do-it" articles, Letters to the Editor, short communications and relevant images with short descriptions. All submitted material is subject to a strict peer-review process.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Ron AllisonPublisher website
Editorial board by country: 6 in mainland China (about 11%); most named United Kingdom 12, United States 11, Mainland China 6, Poland 4, Brazil 3 (54 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Photodynamic Therapy Research StudiesMedicine30.3%
- Nanoplatforms for cancer theranosticsEngineering12.7%
- Laser Applications in Dentistry and MedicineMedicine7.9%
- Nonmelanoma Skin Cancer StudiesMedicine5.1%
- Retinal Diseases and TreatmentsMedicine4.3%
- Skin Protection and AgingMedicine3.2%
- Oral microbiology and periodontitis researchDentistry3%
- Endodontics and Root Canal TreatmentsDentistry2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedCurrent ContentsPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.64LetPub ·
- Impact factor (publisher)
- 2.7Publisher website ·
- CiteScore 2026-06
- 5.6LetPub ·
- CiteScore (publisher)
- 5.6Publisher website ·
- SJR 2026-06
- 0.61LetPub ·
- SNIP 2026-06
- 0.82LetPub ·
- h-index
- 41LetPub ·
- h-index
- 89OpenAlex ·
- i10-index
- 2,286OpenAlex ·
- 2-year mean citedness
- 2.02OpenAlex ·
- Self-citation rate
- 11.1%LetPub ·
- Share of gold OA articles
- 62.85%LetPub ·
Volume
- Articles per year
- 377LetPub ·
Articles by year OpenAlex count · 6,631 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 327 | 327 | 101 |
| 2025 | 852 | 852 | 1,084 |
| 2024 | 491 | 491 | 2,181 |
| 2023 | 660 | 169 | 4,244 |
| 2022 | 514 | 96 | 6,094 |
| 2021 | 515 | 123 | 8,471 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
56 daysMedian, submission to acceptance · P25–P75 35 days – 78 days
- Acceptance to online
- median 1 days (129 articles)
- Submission to online
- median 57 days
- Sample
- 129 articles with submission and acceptance dates (887 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 20 daysPublisher website ·
- Submission to acceptance
- 55 daysPublisher website ·
- Acceptance to publication
- 1 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,960 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,610 / EUR 2,440 / GBP 2,090 / JPY 323,720 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted12, with length limits
- case reportResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- correspondenceResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- editorialResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- editorialsAlthough most Editorials in the journal are commissioned, authors may contact the Editor-in-Chief to request submission of their own Editorial.Length not stated
- letterResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- research paperResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- research papersResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere.Length not stated
- reviewResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- review articleResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…Length not stated
- review articlesReview articles, including institutional reviews of recent developments are welcome, and will undergo peer review.Length not stated
- short communicationResearch Papers should report original clinical studies or research not previously published or being considered for publication elsewhere. Work in Progress may…main text ≤ 1,000 words
- short communicationsShort Communications should not exceed 1000 words and should consist of a background section (not to exceed 100 words), aims (not to exceed 50 words), methods (…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Double anonymized peer review Model summary
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- Frequency
- Quarterly
- Founded
- 2004
- ISSN
- 1572-1000
- Electronic ISSN
- 1873-1597
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Photodiagnosis and Photodynamic Therapy
What CAS zone is Photodiagnosis and Photodynamic Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Photodiagnosis and Photodynamic Therapy is in Zone 3 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Photodiagnosis and Photodynamic Therapy?
The latest impact factor listed by LetPub is 2.64; CiteScore 5.6, h-index 89.
How long does peer review take at Photodiagnosis and Photodynamic Therapy?
Based on the dates recorded on 129 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 56 days (interquartile range 35–78 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Photodiagnosis and Photodynamic Therapy based?
Of the 54 board members whose country the journal's board page names, 6 (about 11%) are in mainland China; the countries named most often are United Kingdom (12), United States (11) and Mainland China (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Photodiagnosis and Photodynamic Therapy?
According to LetPub and DOAJ records, Photodiagnosis and Photodynamic Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, PubMed and Current Contents; that list has not been checked against each database.
Is Photodiagnosis and Photodynamic Therapy open access, and what is the APC?
Photodiagnosis and Photodynamic Therapy is a fully open-access journal. APC about USD 2,960.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .